ONCT vs. VTGN, CYTT, DMAC, CLRB, BYSI, CLSD, PMVP, VSTM, LFVN, and PRPH
Should you be buying Oncternal Therapeutics stock or one of its competitors? The main competitors of Oncternal Therapeutics include Vistagen Therapeutics (VTGN), Cyteir Therapeutics (CYTT), DiaMedica Therapeutics (DMAC), Cellectar Biosciences (CLRB), BeyondSpring (BYSI), Clearside Biomedical (CLSD), PMV Pharmaceuticals (PMVP), Verastem (VSTM), LifeVantage (LFVN), and ProPhase Labs (PRPH). These companies are all part of the "pharmaceutical preparations" industry.
Oncternal Therapeutics (NASDAQ:ONCT) and Vistagen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, community ranking, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.
Vistagen Therapeutics has a net margin of -3,073.51% compared to Oncternal Therapeutics' net margin of -3,160.73%. Vistagen Therapeutics' return on equity of -72.10% beat Oncternal Therapeutics' return on equity.
Oncternal Therapeutics presently has a consensus price target of $28.33, suggesting a potential upside of 207.64%. Vistagen Therapeutics has a consensus price target of $19.00, suggesting a potential upside of 392.23%. Given Vistagen Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Vistagen Therapeutics is more favorable than Oncternal Therapeutics.
Oncternal Therapeutics has higher earnings, but lower revenue than Vistagen Therapeutics.
In the previous week, Oncternal Therapeutics had 4 more articles in the media than Vistagen Therapeutics. MarketBeat recorded 6 mentions for Oncternal Therapeutics and 2 mentions for Vistagen Therapeutics. Vistagen Therapeutics' average media sentiment score of 0.94 beat Oncternal Therapeutics' score of 0.14 indicating that Vistagen Therapeutics is being referred to more favorably in the news media.
16.1% of Oncternal Therapeutics shares are held by institutional investors. Comparatively, 78.4% of Vistagen Therapeutics shares are held by institutional investors. 11.2% of Oncternal Therapeutics shares are held by insiders. Comparatively, 1.0% of Vistagen Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Vistagen Therapeutics received 251 more outperform votes than Oncternal Therapeutics when rated by MarketBeat users. Likewise, 72.24% of users gave Vistagen Therapeutics an outperform vote while only 31.91% of users gave Oncternal Therapeutics an outperform vote.
Oncternal Therapeutics has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500. Comparatively, Vistagen Therapeutics has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500.
Summary
Vistagen Therapeutics beats Oncternal Therapeutics on 12 of the 16 factors compared between the two stocks.
Get Oncternal Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ONCT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ONCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oncternal Therapeutics Competitors List
Related Companies and Tools
